These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804 [TBL] [Abstract][Full Text] [Related]
28. [Health economics, pharmacoeconomics and prescriptions in dermatology]. Berdeaux G Ann Dermatol Venereol; 2000 Mar; 127(3):324-8. PubMed ID: 10804314 [No Abstract] [Full Text] [Related]
29. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients]. Puig L Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989 [TBL] [Abstract][Full Text] [Related]
30. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva). Thielen AM; Barde C; Saurat JH Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444 [No Abstract] [Full Text] [Related]
31. Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Gisondi P; Bianchi L; Conti A; Dapavo P; Malagoli P; Piaserico S; Savoia F; Prignano F; Girolomoni G Br J Dermatol; 2017 Dec; 177(6):e325-e326. PubMed ID: 28498543 [No Abstract] [Full Text] [Related]
32. Consecutive use of different biological therapies in the treatment of psoriasis. Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044 [No Abstract] [Full Text] [Related]
33. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184 [TBL] [Abstract][Full Text] [Related]
34. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. Feldman SR; Evans C; Russell MW J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166 [TBL] [Abstract][Full Text] [Related]
35. [What are the objectives of moderate to severe psoriasis treatment?]. Ortonne JP Ann Dermatol Venereol; 2008 Jul; 135 Suppl 5():S281-4. PubMed ID: 18721665 [TBL] [Abstract][Full Text] [Related]
37. Clinical experience with infliximab biosimilar in psoriasis. Ricceri F; Pescitelli L; Lazzeri L; Prignano F Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577 [No Abstract] [Full Text] [Related]
38. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Reich K; Griffiths C; Barker J; Chimenti S; Daudén E; Giannetti A; Gniadecki R; Katsambas A; Langley R; Mrowietz U; Ogilvie A; Ortonne JP; Reider N; Saurat JH Dermatology; 2008; 217(3):268-75. PubMed ID: 18685261 [TBL] [Abstract][Full Text] [Related]
39. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression. Yip L; Harrison S; Foley P Australas J Dermatol; 2008 Nov; 49(4):250-1. PubMed ID: 18855796 [No Abstract] [Full Text] [Related]
40. [Patient education. Information letter on treatment of psoriasis with ustekinumab (Stelara)]. Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011 Ann Dermatol Venereol; 2011 Dec; 138(12):874-5. PubMed ID: 22137636 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]